Patents by Inventor Phillip Herbert Shaw

Phillip Herbert Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030219412
    Abstract: Disclosed is a replication-recombinant virus, preferably an adenovirus that lacks E1a, E1b and E4 ORF 6, capable of infecting an eye and comprising a lens epithelial cell specific promoter driving an ORF encoding at least one protein, which when expressed in lens epithelial cells of an eye suppresses, at the level of the germinative epithelium of the lens of the eye, cellular proliferation which is stimulated by eye surgery and which would otherwise result in secondary cataract formation in the eye. Also disclosed is the use of the recombinant virus for the treatment of an eye, undergoing eye (e.g. cataract) surgery, in order to reduce the incidence of cellular proliferation in the eye following the surgery and thereby to prevent the formation of secondary cataracts.
    Type: Application
    Filed: March 11, 2003
    Publication date: November 27, 2003
    Applicant: University of Lausanne, an institution organized and existing under the laws of Switzerland
    Inventors: Phillip Herbert Shaw, Roland Sahli, Michel Sickenberg, Francis Munier
  • Patent number: 6200799
    Abstract: A replication-defective recombinant virus, preferably an adenovirus that lacks E1a, E1b and E4 ORF 6, capable of infecting an eye and containing a ORF encoding a protein that when expressed in lens epithelial cells of an eye, suppresses, at the level of the germinative epithelium of the lens of the eye, cellular proliferation which is stimulated by eye surgery and which would otherwise result in secondary cataract formation in the eye is disclosed. The ORF, to be expressed, is under the control of a promoter sequence which is expressly exclusively in human lens epithelial cells. The preferred ORFs, to be expressed, include a non-phosphorylatable retinoblastoma ORF, a dominant negative mutant of a human RAS ORF and a Herpes thymidine kinase ORF.
    Type: Grant
    Filed: June 3, 1997
    Date of Patent: March 13, 2001
    Assignee: University of Lausanne
    Inventors: Phillip Herbert Shaw, Roland Sahli, Michel Sickenberg, Francis Munier